Drugs / NLG802
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05469490 | Oct 2022 → Aug 2024 | cancer | Luke, Jason, MD | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT03164603 | Jun 2017 → Apr 2019 | cancer | NewLink Genetics Corporation | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NLG802 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05469490 ↗ |
| Known as | NLG-1564 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650494 ↗ |
| Action | Inhibit | “intended to inhibit the indoleamine 2,3-dioxygenase 1 (IDO1) enzyme” NCT03164603 ↗ |
| Route | Oral | “escalating oral doses of NLG802” NCT03164603 ↗ |
| Target | IDO1 | “intended to inhibit the indoleamine 2,3-dioxygenase 1 (IDO1) enzyme” NCT03164603 ↗ |